Compare Paxman AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 1,199 Million (Small Cap)
224.00
NA
0.00%
-0.27
-4.01%
2.96
Revenue and Profits:
Net Sales:
84 Million
(Quarterly Results - Dec 2025)
Net Profit:
-9 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.89%
0%
8.89%
6 Months
-23.44%
0%
-23.44%
1 Year
-37.18%
0%
-37.18%
2 Years
27.94%
0%
27.94%
3 Years
55.56%
0%
55.56%
4 Years
-8.92%
0%
-8.92%
5 Years
-18.6%
0%
-18.6%
Paxman AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
29.00%
EBIT Growth (5y)
42.35%
EBIT to Interest (avg)
0.01
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.52
Sales to Capital Employed (avg)
1.17
Tax Ratio
6.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.10%
ROE (avg)
5.08%
Valuation key factors
Factor
Value
P/E Ratio
224
Industry P/E
Price to Book Value
2.45
EV to EBIT
63.03
EV to EBITDA
26.83
EV to Capital Employed
3.01
EV to Sales
3.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
4.77%
ROE (Latest)
1.09%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
84.40
86.90
-2.88%
Operating Profit (PBDIT) excl Other Income
5.80
7.80
-25.64%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-8.80
1.30
-776.92%
Operating Profit Margin (Excl OI)
-35.70%
10.90%
-4.66%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is -2.88% vs 16.02% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -776.92% vs 139.39% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
313.30
253.00
23.83%
Operating Profit (PBDIT) excl Other Income
26.30
47.60
-44.75%
Interest
1.00
1.10
-9.09%
Exceptional Items
-0.10
0.00
Consolidate Net Profit
-16.70
40.20
-141.54%
Operating Profit Margin (Excl OI)
13.60%
132.40%
-11.88%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 23.83% vs 20.42% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -141.54% vs 384.34% in Dec 2024
About Paxman AB 
Paxman AB
Pharmaceuticals & Biotechnology
Paxman AB (publ) is a Sweden-based developer of scalp cooling technology. The cooling system aims to reduce the risk of hair loss connected with cytostatic treatment of cancer. The Company offers a stand-alone, mobile electric cooling unit, which markets under the name Paxman Scalp Cooler, which is a liquid-based cooling system that cools down the patients scalp through the silicone hat. The product has two versions - for one or two patients to be cooled at once. Each device contains a built-in touch screen with a menu-controlled graphic user interface to monitor the process. The lightweight system enables patient to participate in other activities. The Company’s primary markets are Great Britain, Scandinavian countries, the Netherlands, Belgium and Australia.






